News

Michel Sadelain Appointed Inaugural Director of the Columbia Initiative in Cell Engineering and Therapy

Columbia University — New York, NY (September 30, 2024) — Michel Sadelain, MD, PhD, has been named the inaugural director of the Columbia Initiative for Cell Engineering and Therapy (CICET) and director of the Cancer Cell Therapy Initiative in the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center. “Today’s announcement underscores Columbia’s … Continued

Read More

Pancreatic cancer hijacks a brain-building protein

CSHL (February 14, 2024) — Scientists at Cold Spring Harbor Laboratory (CSHL) and the University of California, Davis have reached a new breakthrough in pancreatic cancer research—eight years in the making. It could help slow the disease’s deadly spread. In 2017, as a postdoc in CSHL’s Tuveson lab, Chang-il Hwang and collaborators from the Vakoc lab uncovered … Continued

Read More

DOUBLE HELIX MEDALS DINNER HONORING PSF TRUSTEES RAISES MORE THAN $10 MILLION

New York, NY (CSHL) – On November 15, Cold Spring Harbor Laboratory (CSHL) held its 18th annual Double Helix Medals dinner (DHMD) at the American Museum of Natural History in New York City. CBS journalist Lesley Stahl returned to emcee the awards dinner, which honored Neri Oxman & William Ackman and 2018 Nobel laureate Jim Allison. … Continued

Read More

PRESS RELEASE: THE PERSHING SQUARE SOHN CANCER RESEARCH ALLIANCE AWARDS $4.2M TO SEVEN EMERGING TRAILBLAZERS IN CANCER RESEARCH

THE PERSHING SQUARE SOHN CANCER RESEARCH ALLIANCE AWARDS $4.2M TO SEVEN EMERGING TRAILBLAZERS IN CANCER RESEARCH The Pershing Square Sohn Prize Has Committed More Than $35 Million to 59 Scientists in the Greater New York Area to Support Bold Cancer Research NEW YORK, JUNE 7, 2022 (Business Wire) – The Pershing Square Sohn Cancer Research … Continued

Read More

HIV drug shows promise against metastatic cancer

A drug widely used in HIV therapy has shown to stop disease progression in 25 percent of patients with fourth-line metastatic colorectal cancer. Findings from the trial, published in Cancer Discovery, raise the possibility of an unexpected promising direction in cancer treatment, not just colorectal cancer. The drug used in the study was lamivudine, a reverse transcriptase inhibitor. … Continued

Read More

Hands, Feet, and Fins: The Connection That Explains Acral Melanoma

To understand cancer in humans, researchers at the Sloan Kettering Institute (SKI) are turning to our distant relatives from 425 million years ago: fish. A lot has evolved since then: Fish use their fins to swim, whereas we use our hands to play Wordle. But there remains a deep similarity, explains 2017 Pershing Square Sohn Prize winner Richard … Continued

Read More

SKI Scientists Discover a New Twist on an 80-Year-Old Biochemical Pathway

Every year, thousands of biochemistry majors and medical students around the world learn to memorize the major biochemical pathways that allow cells to function. How these 10 or so pathways are described in textbooks hasn’t changed much since the early 20th century, when they were first discovered. But with the resurgence of interest in cancer metabolism in … Continued

Read More

Old Drug May Have New Trick: Protecting Against COVID-19 Lung Injury

An FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury and the risk of blood clots in severe COVID-19 and other disorders that cause immune-mediated damage to the lungs, according to a preclinical study from researchers at Weill Cornell Medicine and Cold Spring Harbor Laboratory. The … Continued

Read More

Can mRNA Vaccines Fight Pancreatic Cancer? MSK Clinical Researchers Are Trying to Find Out

Messenger RNA (mRNA) vaccines may be the hottest thing in science now as they help turn the tide against COVID-19. But even before the pandemic began, Memorial Sloan Kettering researchers had already been working to use mRNA vaccine technology to treat cancer. Vinod Balachandran a physician-scientist affiliated with the David M. Rubenstein Center for Pancreatic Cancer Research and … Continued

Read More

PRESS RELEASE: THE PERSHING SQUARE SOHN CANCER RESEARCH ALLIANCE AWARDS $3.6 MILLION TO SIX EMERGING PIONEERS IN CANCER RESEARCH

THE PERSHING SQUARE SOHN CANCER RESEARCH ALLIANCE AWARDS $3.6 MILLION TO SIX EMERGING PIONEERS IN CANCER RESEARCH  The Pershing Square Sohn Prize Has Committed More Than $30 Million to 52 Scientists in the New York Area to Support Bold Cancer Research NEW YORK, MAY 18, 2021 (Business Wire) – The Pershing Square Sohn Cancer Research … Continued

Read More